PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy

What this Trial Is About

Researchers are evaluating the Fetal Medicine Foundation's pre-eclampsia risk calculator by using maternal characteristics, first trimester serum placental growth factor (PlGF), and mean arterial pressure (MAP) in a general Finnish pregnant population. The study focuses on pre-eclampsia, intrauterine growth restriction, and polycystic ovary syndrome (PCOS), aiming to identify women at risk for placental dysfunction during pregnancy. This observational study will recruit 3000 pregnant women in the Oulu area and includes substudies investigating children's health and pregnancy characteristics in women with PCOS. Participants will be divided into risk, control, and PCOS groups based on the pre-eclampsia risk calculator and a questionnaire applying Rotterdam criteria for PCOS. Blood samples will be collected during the first and third trimesters. Certain groups will have additional ultrasound scans at 30-32 weeks gestation. Fathers and children will also be recruited for long-term follow-up. The study includes substudies investigating placental insufficiency, iron deficiency, and pregnancy outcomes related to PCOS. During the study, participants will provide blood samples and complete questionnaires. Ultrasound scans and pregnancy monitoring occur at specified gestational weeks. Researchers will track pregnancy-associated hypertension, birth outcomes, and child development through clinical examinations and blood tests up to 12 months of age. Fathers and children will be followed with health data collected from national registers until children reach 15 years. The study aims to measure various maternal and child health outcomes including blood markers, growth, and pregnancy complications.

PEPPI Study: Identification of Women at Risk for Placental Dysfunction